ArticleJournal of asthma and allergy2026
Glucagon-Like Peptide-1 Receptor Agonists vs Dipeptidyl Peptidase-4 Inhibitor Use on Risk of Asthma Exacerbation Among Diabetic Patients with Co-Morbid Asthma in Hong Kong.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Co-existing asthma and diabetes mellitus (DM) are common, and there has been a debate on whether glucagon-like peptide-1 (GLP-1)-based therapies, such as GLP-1 receptor agonists (GLP-1RA) and inhibitors of dipeptidyl peptidase-4 (DPP-4i), confer benefits in these patients due to their anti-inflammatory effects in chronic inflammatory diseases. Methods: A territory-wide retrospective cohort study was conducted in Hong Kong among adult patients with co-existing asthma and DM to examine the impact of add-on GLP-1RA or DPP-4i on asthma exacerbations, ranging from mild exacerbations managed in outpatient settings to severe exacerbations requiring hospitalization. Adult patients were prescribed DPP-4i or GLP-1RA in year 2018 and for at least 6 months in Hospital Authority of Hong Kong were included. These patients were followed till 31st December 31, 2023. Propensity score matching was performed using optimal full matching, which is a sub-classification-based approach in which treated and control subjects are assigned to matched subclasses. Results: A total of 3295 patients with both asthma and DM, 3193 treated with DPP-4i and 102 treated with GLP-1RA, were included in the study. There were 1191 (36.1%) male patients with a mean age of 68.0 ± 14.2 years. There were 2531 (76.8%) patients with moderate-to-severe asthma according to Global Initiative for Asthma (GINA) Steps 3 to 5. GLP-1RA-treated patients had significantly lower risks of hospitalized asthma exacerbation (Average Treatment Effect on the Treated (ATT) Mean Ratio of 0.513, p < 0.001), ad hoc outpatient visits with OCS (ATT Mean Ratio of 0.343, p = 0.005), emergency visits (ATT Mean Ratio of 0.378, p = 0.009), and all asthma exacerbations (ATT Mean Ratio of 0.419, p < 0.001) compared with the DPP-4i group. Conclusion: GLP-1RA, compared with DPP-4i, as an add-on treatment for patients with co-existing DM and asthma was associated with a lower risk of asthma exacerbation. The use of GLP-1RA among diabetic patients with comorbid asthma may be considered though validation in clinical trials is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.